Article Type
Changed
Fri, 04/17/2020 - 08:25

In this supplement, Paul P. Dobesh, PharmD, examines NVAF in the obese and morbidly obese patient population with a focus on anticoagulant treatment options. Topics include: 

  • Understanding the obesity risk in patients with NVAF
  • Challenges of anticoagulation with warfarin in patients with obesity
  • NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

 

Sponsor
Sponsored by Janssen Pharmaceuticals, Inc.
Publications
Sections
Sponsor
Sponsored by Janssen Pharmaceuticals, Inc.
Sponsor
Sponsored by Janssen Pharmaceuticals, Inc.

In this supplement, Paul P. Dobesh, PharmD, examines NVAF in the obese and morbidly obese patient population with a focus on anticoagulant treatment options. Topics include: 

  • Understanding the obesity risk in patients with NVAF
  • Challenges of anticoagulation with warfarin in patients with obesity
  • NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

 

In this supplement, Paul P. Dobesh, PharmD, examines NVAF in the obese and morbidly obese patient population with a focus on anticoagulant treatment options. Topics include: 

  • Understanding the obesity risk in patients with NVAF
  • Challenges of anticoagulation with warfarin in patients with obesity
  • NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Sponsored Supplement
Gate On Date
Mon, 11/25/2019 - 15:15
Un-Gate On Date
Mon, 11/25/2019 - 15:15
Use ProPublica
CFC Schedule Remove Status
Mon, 11/25/2019 - 15:15
Hide sidebar & use full width
render the right sidebar.